

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

NuSynth Technologies raises Rs 36.5 Cr to strengthen India's chemical innovation capabilities for pharma sector

13 October 2026 | News

To build an R&D-led process innovation collaborative platform for complex chemistry



Mysuru-based startup NuSynth Technologies, an R&D-led process innovation collaborative platform for complex chemistry, has raised RS 36.5 crore in Seed funding. The round was co-led by Avaana Capital and Shastra VC.

Over the last two decades, India has built significant capacity in chemical manufacturing. However, many critical molecules continue to rely on complex, multi-step synthesis routes that carry higher material and energy cost, use import-dependent intermediates and hazardous reagents, and pose challenges during commercial scale-up.

This creates a compelling opportunity to deepen domestic R&D and build native chemical process innovation capabilities that yield higher efficiency, sustainability, and commercial scalability.

NuSynth addresses this challenge by redesigning chemical processes from first principles, not through incremental tweaks. By re-evaluating starting materials, reaction pathways, and process economics, their platform develops synthetic routes engineered for superior cost efficiency, yield, cycle time, safety, sustainability, and scalability.

Beginning with high-value sectors like pharmaceuticals and electronics chemicals, the company building process innovation capability that extends across multiple chemistry-led sectors, over time.

"Over the last two decades, India has built significant strength at manufacturing established chemistry. We believe the next chapter will be defined by our ability to innovate on the underlying chemistry itself," said Poorvank Purohit, Co-Founder & CEO, NuSynth Technologies.

The new capital will support the development of NuSynth's R&D and technology capabilities, initial portfolio of proprietary processes, scale-up capabilities and team.

Shruti Srivastava, Partner, Avaana Capital, said: "The next phase of India's growth in high-performance industrial chemistry will increasingly be shaped by the ability to originate proprietary synthesis pathways that are fundamentally more efficient and commercially scalable over time."